Advanced Proteome Therapeutics Corporation (APTCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | - USD | -100.0% |
| 2022 | 331.77 Thousand USD | 2.12% |
| 2021 | 324.88 Thousand USD | 9.49% |
| 2020 | 296.72 Thousand USD | 53.17% |
| 2019 | 193.72 Thousand USD | 263.13% |
| 2018 | 53.34 Thousand USD | -55.23% |
| 2017 | 119.17 Thousand USD | -15.79% |
| 2016 | 141.52 Thousand USD | 97081.21% |
| 2015 | 145.63 USD | 0.0% |
| 2014 | 145.63 USD | -8.86% |
| 2013 | 159.79 USD | -99.9% |
| 2012 | 157.59 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 60 Thousand USD | -97.79% |
| 2004 | 2.72 Million USD | -7.83% |
| 2003 | 2.95 Million USD | -70.36% |
| 2002 | 9.95 Million USD | -2.5% |
| 2001 | 10.21 Million USD | -0.96% |
| 2000 | 10.31 Million USD | 0.11% |
| 1999 | 10.3 Million USD | 87.63% |
| 1998 | 5.49 Million USD | 0.0% |
| 1997 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - USD | 0.0% |
| 2023 Q1 | 320.38 Thousand USD | -3.43% |
| 2023 Q2 | 388.55 Thousand USD | 21.28% |
| 2023 FY | - USD | -100.0% |
| 2023 Q3 | 30.79 Thousand USD | -92.08% |
| 2023 Q4 | - USD | -100.0% |
| 2022 FY | 331.77 Thousand USD | 2.12% |
| 2022 Q3 | 612.89 Thousand USD | 50.95% |
| 2022 Q4 | 331.77 Thousand USD | -45.87% |
| 2022 Q2 | 406.01 Thousand USD | 20.2% |
| 2022 Q1 | 337.76 Thousand USD | 3.97% |
| 2021 Q2 | 368.71 Thousand USD | 9.35% |
| 2021 Q4 | 324.88 Thousand USD | -4.54% |
| 2021 Q3 | 340.31 Thousand USD | -7.7% |
| 2021 Q1 | 337.17 Thousand USD | 13.63% |
| 2021 FY | 324.88 Thousand USD | 9.49% |
| 2020 Q3 | 362.26 Thousand USD | 16.46% |
| 2020 FY | 296.72 Thousand USD | 53.17% |
| 2020 Q1 | 199.55 Thousand USD | 3.01% |
| 2020 Q2 | 311.05 Thousand USD | 55.87% |
| 2020 Q4 | 296.72 Thousand USD | -18.09% |
| 2019 FY | 193.72 Thousand USD | 263.13% |
| 2019 Q1 | 54.38 Thousand USD | 1.94% |
| 2019 Q3 | 186.11 Thousand USD | 232.81% |
| 2019 Q4 | 193.72 Thousand USD | 4.09% |
| 2019 Q2 | 55.92 Thousand USD | 2.83% |
| 2018 Q4 | 53.34 Thousand USD | 3.75% |
| 2018 Q1 | 110.07 Thousand USD | -7.63% |
| 2018 Q3 | 51.42 Thousand USD | -58.47% |
| 2018 FY | 53.34 Thousand USD | -55.23% |
| 2018 Q2 | 123.81 Thousand USD | 12.48% |
| 2017 FY | 119.17 Thousand USD | -15.79% |
| 2017 Q3 | 184.45 Thousand USD | 95631.85% |
| 2017 Q4 | 119.17 Thousand USD | -35.39% |
| 2017 Q2 | 192.68 USD | 0.92% |
| 2017 Q1 | 190.94 USD | 25.04% |
| 2016 Q2 | 149.17 USD | 1.2% |
| 2016 Q4 | 152.70 USD | 1.17% |
| 2016 FY | 141.52 Thousand USD | 97081.21% |
| 2016 Q1 | 147.40 USD | 1.21% |
| 2016 Q3 | 150.93 USD | 1.18% |
| 2015 FY | 145.63 USD | 0.0% |
| 2015 Q1 | 147.40 USD | 1.21% |
| 2015 Q3 | 150.94 USD | 1.19% |
| 2015 Q4 | 145.63 USD | -3.51% |
| 2015 Q2 | 149.17 USD | 1.2% |
| 2014 Q1 | 161.55 USD | 1.11% |
| 2014 Q2 | 156.25 USD | -3.28% |
| 2014 Q3 | 150.94 USD | -3.4% |
| 2014 FY | 145.63 USD | -8.86% |
| 2014 Q4 | 145.63 USD | -3.52% |
| 2013 Q3 | 158.02 USD | -99.92% |
| 2013 Q4 | 159.79 USD | 1.12% |
| 2013 Q2 | 191.3 Thousand USD | 9.66% |
| 2013 FY | 159.79 USD | -99.9% |
| 2013 Q1 | 174.44 Thousand USD | 10.7% |
| 2012 FY | 157.59 Thousand USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | 178.07 Thousand USD | 0.0% |
| 2012 Q4 | 157.59 Thousand USD | -11.5% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2007 Q3 | - USD | -100.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | 147.74 Thousand USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2006 FY | - USD | -100.0% |
| 2006 Q1 | - USD | -100.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2005 Q3 | 2.7 Million USD | -0.0% |
| 2005 FY | 60 Thousand USD | -97.79% |
| 2005 Q1 | 2.71 Million USD | -0.4% |
| 2005 Q4 | 60 Thousand USD | -97.78% |
| 2005 Q2 | 2.7 Million USD | -0.14% |
| 2004 FY | 2.72 Million USD | -7.83% |
| 2004 Q4 | 2.72 Million USD | 0.14% |
| 2004 Q3 | 2.71 Million USD | 0.0% |
| 2004 Q2 | 2.71 Million USD | -0.41% |
| 2004 Q1 | 2.72 Million USD | -7.59% |
| 2003 Q1 | 10 Million USD | 0.46% |
| 2003 FY | 2.95 Million USD | -70.36% |
| 2003 Q2 | 3.01 Million USD | -69.86% |
| 2003 Q3 | 2.98 Million USD | -1.04% |
| 2003 Q4 | 2.95 Million USD | -1.08% |
| 2002 Q4 | 9.95 Million USD | 0.89% |
| 2002 FY | 9.95 Million USD | -2.5% |
| 2002 Q1 | 9.9 Million USD | -2.98% |
| 2002 Q2 | 9.79 Million USD | -1.11% |
| 2002 Q3 | 9.87 Million USD | 0.74% |
| 2001 Q4 | 10.21 Million USD | 4.57% |
| 2001 FY | 10.21 Million USD | -0.96% |
| 2001 Q2 | 9.6 Million USD | -6.09% |
| 2001 Q1 | 10.22 Million USD | -0.81% |
| 2001 Q3 | 9.76 Million USD | 1.68% |
| 2000 Q2 | 10.29 Million USD | -0.31% |
| 2000 Q1 | 10.33 Million USD | 0.28% |
| 2000 Q3 | 10.26 Million USD | -0.35% |
| 2000 FY | 10.31 Million USD | 0.11% |
| 2000 Q4 | 10.31 Million USD | 0.49% |
| 1999 FY | 10.3 Million USD | 87.63% |
| 1999 Q1 | 5.5 Million USD | 0.31% |
| 1999 Q4 | 10.3 Million USD | 76.79% |
| 1999 Q2 | 5.49 Million USD | -0.25% |
| 1999 Q3 | 5.82 Million USD | 6.07% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 FY | 5.49 Million USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q4 | 5.49 Million USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 100.0% |
| SQZ Biotechnologies Company | 27.47 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 100.0% |
| Mesoblast Limited | 118.7 Million USD | 100.0% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 100.0% |
| Genus plc | 233.1 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 100.0% |
| Marizyme, Inc. | 18.71 Million USD | 100.0% |
| ContraFect Corporation | 2.88 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 100.0% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 100.0% |
| MultiCell Technologies, Inc. | 202.58 USD | 100.0% |
| Accustem Sciences Inc. | - USD | NaN% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 100.0% |
| EV Biologics, Inc. | 1.49 Million USD | 100.0% |
| Q BioMed Inc. | 4.1 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 100.0% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 100.0% |
| Biomind Labs Inc. | 735.54 Thousand USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Pharming Group N.V. | 171.54 Million USD | 100.0% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 100.0% |
| Skye Bioscience, Inc. | 4.61 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 100.0% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | 100.0% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 100.0% |
| IMV Inc. | 28.88 Million USD | 100.0% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | 100.0% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 100.0% |
| GB Sciences, Inc. | 1.75 Million USD | 100.0% |
| Alpha Cognition Inc. | 1.22 Million USD | 100.0% |
| HST Global, Inc. | 98.31 Thousand USD | 100.0% |
| CSL Limited | 12.18 Billion USD | 100.0% |
| Halberd Corporation | 150 Thousand USD | 100.0% |
| Enzolytics Inc. | 996.33 Thousand USD | 100.0% |
| Resverlogix Corp. | 6.49 Million USD | 100.0% |
| Affymax, Inc. | - USD | NaN% |
| SYBLEU INC | 477.5 Thousand USD | 100.0% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 100.0% |
| argenx SE | 20 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | - USD | NaN% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | - USD | NaN% |
| AVAX Technologies, Inc. | - USD | NaN% |
| Zenith Capital Corp. | 10.22 Thousand USD | 100.0% |
| Genscript Biotech Corporation | 417.73 Million USD | 100.0% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 100.0% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Helix BioMedix, Inc. | - USD | NaN% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | 100.0% |
| BioStem Technologies, Inc. | 4.71 Million USD | 100.0% |
| ONE Bio Corp. | 19.71 Million USD | 100.0% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 100.0% |
| Burzynski Research Institute, Inc. | - USD | NaN% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 100.0% |
| Agentix Corp. | 50 Thousand USD | 100.0% |
| LadRx Corporation | 33.6 Thousand USD | 100.0% |
| Cell Source, Inc. | 9.25 Million USD | 100.0% |
| ProtoKinetix, Incorporated | - USD | NaN% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 100.0% |
| NovAccess Global Inc. | 2.19 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 100.0% |
| Itoco Inc. | 228.37 Thousand USD | 100.0% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 100.0% |
| Kadimastem Ltd | 891.22 Thousand USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 100.0% |
| CytoDyn Inc. | 30.07 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | - USD | NaN% |
| Mobile Lads Corp. | 484.28 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | - USD | NaN% |
| Qrons Inc. | 351.84 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 100.0% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | 310 Thousand USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 100.0% |
| International Stem Cell Corporation | 4.17 Million USD | 100.0% |
| Bioxytran, Inc. | 1.92 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | 2.18 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | 8.31 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | 1.55 Million USD | 100.0% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 100.0% |
| Neutra Corp. | 54.15 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 100.0% |
| PureTech Health plc | 25.51 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 100.0% |
| IXICO plc | 472.02 Thousand USD | 100.0% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 100.0% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 100.0% |
| CSL Limited | 12.18 Billion USD | 100.0% |
| Cellectis S.A. | 92.77 Million USD | 100.0% |